

COST SAVING ASSOCIATED WITH ROMIPLOSTIM REPACKAGING IN PATIENT WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA

J.C. DEL RÍO VALENCIA, C. ORTEGA DE LA CRUZ, R. TAMAYO BERMEJO, A. LUNA HIGUERA
REGIONAL UNIVERSITY HOSPITAL OF MÁLAGA, PHARMACY SERVICE, MÁLAGA, SPAIN.

B02

Background

Romiplostim is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (corticosteroids, immunoglobulins). This drug has an important economic impact, in this sense it has been decided to start a protocol for the use of romiplostim which has been established to group patients or dispense two repackaged romiplostim pre-filled syringes for each patient fractionating vials according to the patient's dose in syringes as a saving strategy.

Objective

Evaluating and quantifying the cost saving of the optimization of the use of romiplostim vials through repackaging into syringe under aseptic conditions.


Material and Methods

Retrospective study from January-June 2023 and patients diagnosed from ITP and treated with romiplostim were included.

A protocol is being implemented, which consists of dispensing two repackaged romiplostim pre-filled syringes (7 days expiration according to Good Practice Guide of preparation of medications in hospital Pharmacy Service) for each patient or grouping the patients receiving treatment with romiplostim and fractionating the vial in syringes to adjust to the recommended dose according to the summary of product characteristics in a flow laminar cabinet.

- **Demographic data:** age and sex.
- **Number of patients.**
- **Economic data.**
- Data were collected from pharmacy electronic dispensing records.

Results



- This treatment has cost a total of €240.561,95 for these six months (January-June).
- if patients had been dispensed two repackaged romiplostim pre-filled syringes, the total cost had been €158191,48
- Therefore, the cost saving there would be €82.370,47 (€164.740,94/year).

Conclusion

The repackaging could represent a significant economic saving in the treatment of idiopathic thrombocytopenic purpura, while contributing to maintaining the sustainability of the national health system.

